Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.

    Article  CAS  Google Scholar 

  2. Germing U, Kundgen A, Gattermann N . Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004; 45: 1311–1318.

    Article  CAS  Google Scholar 

  3. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, van Biezen A et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 67–73.

    Article  Google Scholar 

  4. Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005; 11: 713–720.

    Article  Google Scholar 

  5. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q− deletion. N Engl J Med 2006; 355: 1456–1465.

    Article  CAS  Google Scholar 

  6. Lancet JE, List AF, Moscinski LC . Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007; 21: 586–588.

    Article  CAS  Google Scholar 

  7. Giagounidis AA, Germing U, Aul C . Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006; 12: 5–10.

    Article  CAS  Google Scholar 

  8. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L et al. Narrowing and genomic annotation of the commonly deleted region of the 5q− syndrome. Blood 2002; 99: 4638–4641.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all technicians for excellent assistance in performing cytogenetic studies.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to U Platzbecker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Platzbecker, U., Mohr, B., von Bonin, M. et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 21, 2384–2385 (2007). https://doi.org/10.1038/sj.leu.2404811

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404811

This article is cited by

Search

Quick links